Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Evaluating the benefit of pharmacologic agents in treating IBS

May's issue of the Alimentary Pharmacology & Therapeutics evaluates the functional net value of pharmacologic agents in treating irritable bowel syndrome.

News image

The recent FDA provisional endpoint incorporates a one-tailed measure of improvement for IBS based on the underlying motility complaint.

However, motility exists along a spectrum.

Patients may experience diarrhea resulting from therapy for their constipation-predominant IBS (IBS-C) or constipation during treatment for diarrhea-predominant IBS (IBS-D), but still meet a unidirectional motility-based FDA endpoint.

Drs Shah and Pimentel from California, USA weighed the reported efficacy of existing therapies based on patient-reported outcomes with negative intestinal side effects in controlled clinical trial data.

The team analyzed the difference between ‘attributable risk’ of efficacy based on number needed to treat (NNT) in the literature and percentage of adverse events (AE) of opposite intestinal complaints in placebo-controlled trials identified through a literature search of IBS trials.

This calculation was coined ‘functional net value’ (FNV) or net benefit of the given drug.

Linaclotide caused diarrhea in 15% resulting in negative FNV
Alimentary Pharmacology & Therapeutics

The researchers found that for treating IBS-C, lubiprostone caused diarrhea in excess of placebo in 4% of patients, leading to a FNV of 3.9 percentage units.

The team noted that linaclotide caused diarrhea in 15% resulting in negative FNV.

For IBS-D, the team found that alosetron and tricyclic anti-depressants caused constipation among a respective 17% and 13% resulting in a FNV of −3.6 and −0.5 percentage units.

Among all therapies, only rifaximin did not cause the adverse event opposite the underlying motility complaint and the drug only had benefit, not detriment.

Dr Pimentel's team concludes, "Functional net value (FNV) offers a method of evaluating the net benefit of a drug in IBS."

"Most IBS treatments have a negative effect on IBS that exceeds the benefits."

Aliment Pharmacol Ther 2014: 39(9): 973–983
16 April 2014

Go to top of page Email this page Email this page to a colleague

 24 November 2014

Advanced search
 24 November 2014 
Adhesions in abdominal and pelvic surgery
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD
 21 November 2014 
Skin cancer in ulcerative colitis patients
 21 November 2014 
Mortality of chemoembolization in hepatocellular carcinoma
 21 November 2014 
Hepatic involvement in IgG4-related disease
 20 November 2014 
Global measures in chronic idiopathic constipation
 20 November 2014 
Macrophage activation in alcoholic hepatitis
 20 November 2014 
Covert hepatic encephalopathy and survival
 19 November 2014 
Thiopurine withdrawal in IBD
 19 November 2014 
Esophageal narrowing in esophageal eosinophilia
 19 November 2014 
Second intestinal resection in Crohn's
 18 November 2014 
Colorectal neoplasia and vitamin D
 18 November 2014 
Food-associated changes in the intestinal mucosa in IBS
 18 November 2014 
Alternative medicine use by US adults
 17 November 2014 
Treatment of obesity in primary care settings
 17 November 2014 
Allergy-related diseases and abdominal pain in childhood
 17 November 2014 
Diagnosis of monogenic very early onset IBD
 14 November 2014 
Second intestinal resection in Crohn's
 14 November 2014 
HCC risk in active stage Hep B
 14 November 2014 
Thiopurine and clinical remission in IBD
 13 November 2014 
Antibiotics and risk of new-onset Crohn’s
 13 November 2014 
Chronic Hep C genotype 1 treatment after relapse
 13 November 2014 
Chemoembolization for hepatocellular carcinoma
 12 November 2014 
Risk of hepatocellular carcinoma
 12 November 2014 
Abdominal symptom severity in chronic idiopathic constipation
 12 November 2014 
Screening colonoscopy
 11 November 2014 
Hepatocellular carcinoma in Hep B with nucleotide analogue
 11 November 2014 
Familial colorectal cancer screening
 11 November 2014 
Fecal microbiota transplant for C. diff
 10 November 2014 
STaples IPAA for ulcerative colitis
 10 November 2014 
Blood stream infections in acute liver failure
 10 November 2014 
Ig4-related disease
 07 November 2014 
Host and viral factors in chronic Hep C
 07 November 2014 
Celiac diagnosis without biopsy
 07 November 2014 
Pricing practices of gastroenterologists
 06 November 2014 

Colorectal surgery postdischarge occurrences and readmissions

 06 November 2014 
Thromboprophylaxis in IBD
 06 November 2014 
Steatosis biomarkers in NAFLD
 05 November 2014 
Readmission risk factors for patients with IBD
 05 November 2014 
Hysterectomy and colonoscopy completion
 05 November 2014 
Adalimumab in Crohn's disease
 04 November 2014 
Gut barrier dysfunction and CNS disorders
 04 November 2014 
Hemospray for nonvariceal upper GI bleeding
 04 November 2014 
Sleep duration and ulcerative colitis
 03 November 2014 
Mucosal pathophysiology in HIV and IBD
 03 November 2014 
Managing bleeding gastroduodenal ulcers
 03 November 2014 
Identifying inflammation in ulcerative colitis
 31 October 2014 
Pregnancy complications in celiac disease
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
C. difficile infection with metronidazole
 30 October 2014 
Cirrhosis in women
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Constipation and colorectal cancer
 29 October 2014 
Quality of life after infection with E. coli
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 28 October 2014 
Risk factor for smaller final height in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us